Callodine Capital Management LP Purchases 109,240 Shares of Sanofi $SNY

Callodine Capital Management LP grew its position in Sanofi (NASDAQ:SNY) by 26.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 515,209 shares of the company’s stock after acquiring an additional 109,240 shares during the period. Sanofi accounts for 2.6% of Callodine Capital Management LP’s portfolio, making the stock its 15th largest holding. Callodine Capital Management LP’s holdings in Sanofi were worth $24,890,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of SNY. Voya Investment Management LLC increased its stake in shares of Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock valued at $11,460,000 after buying an additional 21,540 shares in the last quarter. Ascent Group LLC bought a new stake in Sanofi during the 1st quarter worth about $426,000. 1248 Management LLC acquired a new stake in Sanofi in the 1st quarter valued at about $518,000. Equity Investment Corp raised its stake in shares of Sanofi by 2.5% in the second quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock worth $121,376,000 after acquiring an additional 62,109 shares during the last quarter. Finally, CGN Advisors LLC acquired a new position in shares of Sanofi during the second quarter worth approximately $1,694,000. 14.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Sanofi in a report on Monday, December 1st. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Price Performance

SNY opened at $49.53 on Friday. The company has a fifty day moving average price of $49.90 and a two-hundred day moving average price of $49.18. The firm has a market capitalization of $121.62 billion, a PE ratio of 11.60, a P/E/G ratio of 1.35 and a beta of 0.44. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 24th. The company reported $2.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The business had revenue of $15.46 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period last year, the company earned $2.25 EPS. The firm’s revenue was down 7.5% on a year-over-year basis. As a group, analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.